Treatment of Guillain-Barré Syndrome When Unable to Walk Unaided (GBS Disability Score Grade 3 or More)

In Guillain-Barré syndrome, the degree of functional impairment guides the decision to initiate treatment. Patients who can no longer walk without assistance—or who retain that ability but develop swallowing difficulties or autonomic disturbances—meet the threshold for prompt intervention.

Clinical Scenario

This protocol covers patients who are unable to walk unaided (GBS disability score grade 3 or more) within 4 weeks from onset of weakness. It also applies to patients still able to walk unaided but who present with swallowing difficulties or autonomic disturbances.

Treatment Approach

Immunotherapy is strongly recommended to be started as soon as possible for patients meeting this clinical threshold. In cases where a treatment-related fluctuation (TRF) occurs, repeating a course of immunotherapy may be considered—the specific options, eligibility criteria, and sequencing are detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/jns.12594

The TF strongly recommends starting PE as soon as possible in GBS patients unable to walk unaided (GBS-DS grade 3 or more) and within 4 weeks from onset.
The TF strongly recommends starting IVIg as soon as possible in patients unable to walk unaided (GBS-DS grade 3 or more) if still within the first 2 weeks from onset of weakness.
The TF suggests (GPP) that patients still able to walk but having features like swallowing difficulties or autonomic disturbances are also eligible for treatment.
Observational data indicate that a repeated course of IVIg or PE can be effective in case of a TRF (see text).

View source ↗